Search
Custirsen
go.drugbank.com/drugs/DB05487InvestigationalCustirsen acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells.
Glymidine
go.drugbank.com/drugs/DB01382ApprovedIt is used for the concomitant use with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus.
Ancrod
go.drugbank.com/drugs/DB05099ApprovedWithdrawnAncrod, marketed as Viprinex, is a defibrinogenating agent derived from Malayan pit viper venom. The defribrinogenation of blood results in an anticoagulant effect. … Currently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S.
Unasnemab
go.drugbank.com/drugs/DB18837InvestigationalUnasnemab is under investigation in clinical trial NCT04683848 (Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury).
LSZ-102
go.drugbank.com/drugs/DB15362InvestigationalLSZ-102 is under investigation in clinical trial NCT02734615 (Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers).
Macadamia seed oil glycereth-8 esters
go.drugbank.com/drugs/DB14318InvestigationalIt is not an approved drug.
Camrelizumab
go.drugbank.com/drugs/DB14776InvestigationalCamrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
ALM201
go.drugbank.com/drugs/DB17206InvestigationalIt is being investigated in the treatment of various cancers.[A254556]